相关实验视频
Updated: May 7, 2025

00:07
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
7.2K
在甲状腺癌中,针对血管新生和免疫微环境之间的通信的治疗方法
Alessandro Prete1, Carmelo Nucera1,2
1Human thyroid cancers preclinical and translational research program, Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Current opinion in endocrine and metabolic research
|December 30, 2024
概括
新的甲状腺癌疗法,包括向药物和免疫检查点抑制剂,显示出有希望但面临阻力. 结合这些方法可能会改善甲状腺癌患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 甲状腺癌的治疗已经通过向疗法 (例如,BRAF,RET抑制剂),抗血管原剂 (铁氨酸激酶抑制剂) 和免疫检查点抑制剂取得了进展.
- 目前的向和抗血管生成疗法提供部分疗效,并面临瘤耐药性和毒性挑战.
- 免疫疗法在精选的甲状腺癌患者中显示了初步但有希望的结果.
研究的目的:
- 审查和前性讨论非骨髓和骨髓甲状腺癌中的免疫微环境.
- 探索甲状腺癌中免疫和血管原生微环境之间的相互作用.
- 讨论针对这些相互作用的新型组合疗法以及嵌合抗原受体 (CAR) T 细胞的潜力.
主要方法:
- 文献综述和关于甲状腺癌微环境现有研究的前性讨论.
- 在甲状腺瘤中分析血管和免疫成分之间的功能连接.
- 探索治疗策略,包括组合疗法和CAR T细胞.
主要成果:
- 甲状腺癌在他们的血管和免疫微环境之间表现出功能连接.
- 涉及抗血管性,免疫检查点和向药物的联合疗法可以克服药物耐药性.
- 化学抗原受体 (CAR) T细胞在晚期甲状腺癌中提供了持久和有效的反应的潜在途径.
结论:
- 血管新生和免疫微环境之间的相互作用对甲状腺癌的进展和治疗反应至关重要.
- 针对血管新生和免疫途径的组合疗法,以及特定的向疗法,为改善临床结果提供了一个有希望的策略.
- 像CAR T细胞这样的有针对性的方法有可能对晚期甲状腺癌进行更持久,更有效的治疗.
相关概念视频
Tumor Immunotherapy
394
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
394
The Tumor Microenvironment
6.3K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.3K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Cancer Therapies
7.4K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.4K
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Mechanism of Angiogenesis
4.7K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
4.7K

